Has Nandar Swe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $827 in general payments to Nandar Swe, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nandar Swe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nandar Swe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nandar Swe, MD

Internal Medicine · Glendora, CANPI 1730392655

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Novo Nordisk at 37.2% of the total. Reporting peaked in 2020 at $265 and has fallen 81.6% since, to $49 in 2025.

$827in general payments, 2019–2025

Across 45 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$307
Sanofi-aventis U.S. LLC$182
Sanofi$177
Abbott$112
Corcept Therapeutics$49

What the payments were for

Speaking & faculty fees$28735%
Food & beverage$44053%
Education$10012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	26	$307
Sanofi-aventis U.S. LLC	13	$182
Sanofi	2	$177
Abbott	2	$112
Corcept Therapeutics	2	$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SOLIQUA 100/33$105

How this compares

$827 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024

$12,969

Medicare patients

Services billed

207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	237	$326,511
TrulicityDulaglutide	70	$89,554
JanuviaSitagliptin Phosphate	67	$81,779
JardianceEmpagliflozin	55	$71,606
ProliaDenosumab	40	$68,972
Humulin R U-500 KwikpenInsulin Regular, Human	53	$61,606
Tresiba Flextouch U-100Insulin Degludec	68	$59,676
FarxigaDapagliflozin Propanediol	50	$51,124
MounjaroTirzepatide	21	$32,681
TradjentaLinagliptin	33	$30,649
Tresiba Flextouch U-200Insulin Degludec	27	$29,633
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	44	$29,107
Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro	58	$28,880
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	23	$25,733
Humalog Kwikpen U-100Insulin Lispro	50	$20,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$307	$326,511237 claims
Sanofi-aventis U.S. LLCLantus	$182	$2,82914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Glendora

Andrew ChengSouth San Francisco$55.1M
Tung NgoNewport Beach$4.9M
Christian EversullStanford$2.9M
Christian SandrockSacramento$2.1M
Hatim HusainSan Diego$2M
Teck LingPalo Alto$1.1M
Hyong Kimla Jolla$1M
Rohit Loombala Jolla$965K
Fred CohenSan Francisco$929K
Steven EdelmanSan Diego$863K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →